Mike Mensinger, the Chief Product Officer at Beta Bionics, Inc., recently sold 2,650 shares of the company’s common stock. The transaction took place on October 27, 2026, at a price of $22 per share. This sale is significant as it indicates ongoing adjustments in executive ownership, which may reflect personal financial strategies or market conditions.

Background

Beta Bionics, Inc. operates in the surgical and medical instruments and apparatus sector. The company is incorporated in Delaware and has its business address in Irvine, California. Beta Bionics is publicly traded under the ticker symbol BBNX.

What the Filing Says

According to the SEC filing (accession number 0002048500-26-000015), Mensinger's transaction was executed under a Rule 10b5-1 Plan, which allows company insiders to set up a predetermined schedule for selling stocks. The filing notes, "Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025." Following this transaction, Mensinger owns 174,740 shares of Beta Bionics.

Impact

This sale may affect investor perception of Beta Bionics, as insider transactions can influence stock performance and investor confidence. Other executives and stakeholders may also be closely monitoring such sales for trends in executive behavior within the surgical and medical instruments industry.

What's Next

The filing does not say what happens next.